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Abstract
Objectives The primary aim of the study was to gain
insight into the relative risk of clinically relevant oral
candidiasis following inhaled corticosteroid (ICS) initiation
over time. A secondary aim was to analyse the influence of
patient characteristics and co-medication on the occurrence
of this adverse effect.
Methods Drug prescription data from 1994 to 2011 were
retrieved from the IADB.nl database. To study the influ-
ence of ICS use on occurrence of oral candidiasis, a pre-
scription symmetry analysis was used, including patients
using medication for oral candidiasis up to 1 year before or
after ICS initiation. The relative risk was calculated by
dividing the number of patients receiving medication for
oral candidiasis after ICS initiation by the number of
patients receiving the same medication before ICS initia-
tion. Sub-analyses were conducted to compare the relative
risks at several time points after ICS initiation and to
account for therapy persistence by only including chronic
users of ICS. A multivariate logistic regression model was
used to identify predictive factors.
Results A total of 52,279 incident users of ICS therapy
were identified, of which 1,081 received medication for
oral candidiasis up to 1 year before or after ICS initiation.
A total of 701 patients received medication for oral can-
didiasis after ICS initiation, while 361 received these
medications in the reversed sequence, resulting in a
sequence ratio (SR) of 1.94 (95 % CI 1.71–2.21). In the
first 3 months after ICS initiation, the SR was 2.72 (95 %
CI 2.19–3.38) and then decreased to 1.47 (95 % CI
1.11–1.95) 9–12 months after ICS initiation. Predictive
factors were higher daily dose of ICS and concomitant use
of oral corticosteroids.
Conclusions This study found a significant and clinically
relevant increased number of patients receiving medication
for oral candidiasis in the first year after therapy initiation
with ICS. Relative risk is highest in the first 3 months, but
remains increased up to at least 1 year after ICS initiation.
This study stresses the need for patient education and
inhalation instruction.
1 Introduction
Inhaled corticosteroids (ICS) are widely prescribed as
maintenance therapy for respiratory diseases such as
asthma and chronic obstructive pulmonary disease
(COPD). ICS suppress inflammation in the lower airway
tract, thereby reducing inflammation-driven airflow
obstructions and improving disease outcomes. ICS cause
fewer adverse effects than systemic-acting corticosteroids
due to the local mode of action. Nonetheless, adverse
effects still occur, mostly on a local level. The most
common local adverse effects of ICS are oral candidiasis,
dysphonia, pharyngitis and cough [1–3]. These adverse
effects may decrease therapy adherence and quality of life
[2, 4].
Oral candidiasis is thought to be a consequence of
local immunosuppression at the oral mucosal surface by
deposition of ICS particles in the higher respiratory
airways [1, 4]. Importantly, the therapeutic efficacy of
ICS is localized in the lower respiratory airways [5].
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In healthy patients, oral candidiasis primarily leads to
local discomfort such as altered taste sensation, but in
immuno-compromised patients, the local infection may
enter the bloodstream and develop into a potentially sys-
temic life-threatening infection [6]. The main treatments
for oral candidiasis are nystatin mouthwashes or
miconazole oral gels [7]. Local administration of methyl-
rosaniline and amphotericin B may be prescribed in
patients showing insufficient response to nystatin and
miconazole [8].
Various studies have been conducted assessing the
association between ICS and the occurrence of oral can-
didiasis [9–12]. One review reported incidence rates
between 0 and 70 %, based on four studies performed
between 1974 and 1990 using different diagnostic criteria
[2]. A recent meta-analysis reported an odds ratio of 3.6 for
oral candidiasis in ICS users compared with placebo,
regardless of dose or device [13]. This meta-analysis
included 23 randomised controlled trials (RCTs) performed
between 1994 and 2003, with an average follow-up of
12 weeks.
Although incidence and risk factors are well known, the
relative risk during long-term ICS use has not previously
been studied. Furthermore, data from actual clinical prac-
tice as opposed to clinical trials are scarce.
The primary aim of the present study was to gain insight
into the relative risk of clinically relevant oral candidiasis
following ICS initiation over time. The secondary aim was
to analyse the influence of predictive factors such as patient
characteristics and co-medication on the occurrence of this
adverse effect. Results of this study will assist healthcare




Drug dispensing data from Dutch community pharmacies
were obtained from the IADB.nl database, which holds
prescription records of over 500,000 individuals in The
Netherlands. The IADB.nl prescription database has been
validated for drug-utilization studies [14, 15] and has
previously been used for such studies [16]. Dutch patients
usually register at a single community pharmacy and
therefore prescription records can provide an almost com-
plete listing of the subjects’ prescribed drugs [17]. Data in
the database contain information on drug name, anatomical
therapeutic chemical (ATC) classification, dispensing date,
dosage and defined daily dose (DDD) as provided by the
World Health Organization (WHO). Data between January
1994 and December 2011 were used for analyses.
2.2 Analysis and Outcomes
To study the influence of ICS use on occurrence of oral
candidiasis, a prescription symmetry analysis was used.
This method determines whether medication for oral can-
didiasis is prescribed more frequently following ICS initi-
ation than the other way around. A recurrent problem of
other types of analyses, such as case-control or cohort
designs, is the inherent tendency of drugs to accumulate in
certain patients, such as elderly or otherwise frail individ-
uals. The prescription symmetry analysis corrects for these
confounding factors, as long as they remain constant over
time. The advantages and limitations of the method are
discussed in more detail by Hallas [18]. The method has
been used to study the occurrence of side effects for dif-
ferent drug classes [18–20]. The outcome of the prescrip-
tion symmetry analysis is the sequence ratio (SR),
calculated as the number of patients starting ICS first and
medication for oral candidiasis second, divided by the
number of individuals starting these medications in the
reverse sequence. The SR was adjusted for incidence trends
of the drugs, to account for potential increasing or
decreasing prescription incidence over time [18].
The SR is an estimate of the relative risk of oral can-
didiasis in patients receiving ICS compared with patients
not receiving ICS [18, 21]. By including only cases in
which medication was prescribed, the study focused on
clinically relevant oral candidiasis. The 95 % confidence
interval was calculated as eln(SR)±1.969SE, in which SR is
the sequence ratio and SE the standard error, estimated as
H ((1/patients starting ICS first) ? (1/patients starting ICS
second)).
2.3 Population
All incident users of both ICS and medication for oral
candidiasis within a year timespan of each other were
selected for analysis. Incidence was defined as a period of
2 years without use of the study drugs, while being present
in the database. ICS included were beclomethasone, bu-
desonide, fluticasone, ciclesonide and ICS combination
inhalers with long-acting beta agonists. Medication for oral
candidiasis were local oral formulations of nystatin,
miconazole, methylrosaniline and amphotericin B.
2.4 Sub-Analyses
Sub-analyses were conducted to compare the relative risks
at several time points after ICS initiation and to account for
therapy persistence by only including chronic users of ICS.
Chronic use was defined as having at least four follow-up
prescriptions in the year after initial prescription. Further-
more, a sensitivity analysis was performed in which we
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changed the period of no use (‘wash-out’) from 2 to
3 years.
2.5 Potential Effect Modifiers
A multivariate logistic regression model was used to
identify predictive factors of the ‘ICS followed by oral
candidiasis’ order compared with the reverse order,
including low (B10 years) or high (C60 years) age, sex,
year of ICS therapy initiation (per year), total daily dose of
ICS (beclomethasone equivalent), type of inhaler (pres-
surized metered dose inhaler [pMDI], dry powder inhaler
[DPI] or nebulizer) and co-medication with antibacterials
and oral systemic corticosteroids 1 month prior to oral
candidiasis. The influence of co-morbidities known to be
associated with increased frequency of oral candidiasis,
namely diabetes mellitus and HIV [22, 23], was also
determined.
Note that the odds ratios (OR) calculated in the multi-
variate model are not risk factors for oral candidiasis but
rather effect modifiers of the prescription order ‘ICS fol-
lowed by medication for oral candidiasis’.
Statistical analyses were performed using SPSS 18.0.3
(SPSS Inc. Chicago, IL, USA) and Microsoft Excel 2010.
3 Results
A total of 52,279 incident users of ICS therapy were
identified; 1,081 of these were incident users of medication
for oral candidiasis within 1 year before or after ICS ini-
tiation. A total of 19 (1.8 %) patients started both therapies
on the same day and were excluded from further analyses.
In the remaining 1,062 patients, mean age at ICS initiation
was 54.2 ± 20.7 years and 62.6 % were female. A total of
80 (7.5 %) were diabetes patients and none received HIV
medication.
A total of 701 patients received medication for oral
candidiasis after ICS initiation, while 361 received these
medications in the reversed sequence, resulting in an SR of
701/361 = 1.94 (95 % CI 1.71–2.21). The results were not
influenced by time trends in prescribing (correction
factor = 0.999).
3.1 Sub-Analyses
The sub-analysis showed the number of prescriptions for
oral candidiasis medication were highest in the first
3 months after ICS initiation, resulting in an SR of 2.72
(95 % CI 2.19–3.38). This decreased to 1.47 (95 % CI
1.11–1.95) in the 9–12 months after ICS initiation (Fig. 1).
A total of 387 patients were included when using the
criterion for chronic exposure. Of these, 277 patients
started ICS first and 107 started oral candidiasis medication
first, resulting in an SR of 277/107 = 2.59 (95 % CI
2.07–3.24).
When the wash-out period was changed to 3 years, 954
patients were included and this yielded an SR of
629/309 = 2.04 (95 % CI 1.78–2.33).
3.2 Effect Modifiers
The results of the multivariate logistic regression analysis
are shown in Table 1. There was a significantly increased
OR for receiving oral candidiasis medication after ICS
initiation when using a medium daily ICS dose or with
concomitant use of oral corticosteroids. Using a high dose
also increased the OR, although not significantly. Con-
comitant use of antibacterials or use of a pMDI signifi-
cantly decreased the OR. Age, sex or year of ICS initiation
and selected co-morbidities were not significant predictors.
4 Discussion
This study found a significant and clinically relevant
increased number of patients receiving medication for oral
candidiasis in the first year after therapy initiation with
ICS. The relative risk was highest in the first 3 months of
ICS use but remains increased up to at least 1 year after
ICS initiation. In addition, higher dose of ICS and con-
comitant use of oral systemic corticosteroids were predic-
tive factors that strengthen this relationship.
Use of pMDI or concomitant use of antibacterials were
identified as negative predictive factors.
4.1 Comparison with Other Studies
The predictive factors for oral candidiasis medication fol-
lowing ICS initiation identified in our study were high ICS
dose and use of oral systemic corticosteroids. These factors
were also reported in previous studies [1, 2, 4, 11–13].
A meta-analysis of Rachelefsky et al. [13] reported a
3.6-fold greater risk for oral candidiasis following the first
12 weeks after ICS initiation, while we found an approxi-
mately twofold greater risk. This difference may be
explained by the duration of follow-up in studies included
in the meta-analysis, which was approximately 12 weeks,
whereas our study covers a period of 12 months. Indeed,
we noted an increased effect in the first 3 months after ICS
initiation.
Notably, our study reported a decreased risk for oral
candidiasis when using pMDI, while Rachelefsky et al.
reported an increased risk. This may be explained by use of
different ICS drugs, such as high prescription rates for
fluticasone and low rates for mometasone.
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4.2 Strengths and Limitations
By including patients with prescriptions for oral candidia-
sis medication, only clinically relevant oral candidiasis was
included. We included only first time users of both ICS and
medication for oral candidiasis, but we have to consider
that the outcome of our study may be a contraindication for
exposure to ICS. There may be a risk that a physician is
less willing to prescribe ICS to a patient who is already
suffering from oral candidiasis and consequently these
patients will selectively be excluded from the proportion
that is prescribed ICS after oral candidiasis. A limitation of
the prescription database used in our study is that no
indications are recorded. Thus, antifungal drugs may have
been prescribed for other indications, such as intestinal
candidiasis. On the other hand, clinically relevant oral
candidiasis may have remained untreated or treated with
other medications in some patients. However, these limi-
tations are not expected to have an impact on the reported
SR.
Fig. 1 Medication for oral
candidiasis is prescribed more
often following (n = 701) than
before (n = 361) inhaled
corticosteroid (ICS) initiation
Table 1 Variables predicting
the prescription order ‘inhaled
corticosteroids followed by
medication for oral candidiasis’
compared with ‘medication for
oral candidiasis followed by
inhaled corticosteroids’
(n = 1,062)
CI confidence interval, DPI dry
powder inhaler, ICS inhaled
corticosteroid, NA not
applicable, OR odds ratio,
pMDI pressurized metered dose
inhaler
* p \ 0.05
Variable Patients with variable [n (%)] OR 95 % CI
Age
Young age (B10 years) 50 (4.7) 1.143 0.585–2.231
High age (C60 years) 468 (44.1) 0.944 0.712–1.252
Age 11–59 years 544 (51.2) Reference
Female sex 665 (62.6) 0.892 0.678–1.176
Daily dose of ICS
Low dose (B400 lg) 286 (26.9) Reference
Medium dose (401–800 lg) 527 (49.6) 1.402* 1.012–1.942
High dose ([800 lg) 249 (23.4) 1.356 0.928–1.982
Type of inhaler
pMDI 305 (28.7) 0.710* 0.522–0.964
DPI 747 (70.3) Reference
Nebulizer 10 (0.9) 0.497 0.135–1.832
Year of ICS initiation (per year) – 0.974 0.941–1.008
Co-medication
Antibacterials 386 (36.3) 0.579* 0.436–0.770
Oral corticosteroids 221 (20.8) 2.239* 1.552–3.229
HIV 0 (0) NA NA
Diabetes mellitus 80 (7.5) 0.897 0.546–1.474
234 J. F. M. van Boven et al.
Incident ICS use was defined as having not been pre-
scribed the drug for at least 2 years. It is possible that
patients redeemed their ICS prescription before this period,
thereby being incorrectly defined as incident users in our
analysis. A sensitivity analysis was therefore performed in
which the required period of non-use was 3 years; how-
ever, this did not influence the results.
The risk for oral candidiasis is highest in the first month
after ICS initiation and decreases thereafter (Fig. 1). This
may be due to the fact that patient inhalation technique
improves. However, we cannot rule out the fact that
patients discontinue their ICS after first prescription and
are consequently no longer at risk. For some patients,
continuous use of ICS may not be mandatory, but for some
patients, especially those with asthma, ICS are essential
therapy for disease control.
A separate analysis was therefore performed for patients
with chronic ICS exposure. This analysis yielded slightly
higher risk estimates. The interpretation of this result
should take into account the lower patient number available
for analysis because a large number of patients were
excluded. If a patient initiates ICS and a violent oral can-
didiasis occurs shortly after, he or she might not redeem a
second prescription and this might consequently bias the
results.
Furthermore, it is recommended that further study on
this topic should include the use of spacers as a variable in
the regression analysis, because spacers have been shown
to lower oropharyngeal deposition and this may reduce the
occurrence of oral candidiasis [4]. Unfortunately, the use of
spacers was not recorded in the prescription database used
in these analyses.
4.3 Clinical Implications
Although oral candidiasis is a common adverse event of
ICS, the occurrence in the general population over time has
not been studied before. This information may assist
healthcare professionals in developing tailored interven-
tions to prevent oral candidiasis.
Oral candidiasis from ICS use is believed to be mainly
caused by ICS deposition in the higher airways [1]. Proper
inhalation techniques and use of spacer devices, as well
as rinsing the mouth after ICS inhalation, are effective
[24–26] in lowering oropharyngeal ICS deposition, and
thereby may reduce the occurrence of oral candidiasis [4].
Unfortunately, patient education about inhaler devices and
inhalation techniques is not always given and when given,
instruction is often rushed, of poor quality or not reinforced
[27, 28]. This is further complicated by suggestions that
knowledge of correct inhalation techniques decreases
quickly after use in clinical practice [29]. In children,
between 30 % (using one inhaler) and 54 % (using
multiple inhalers) of patients do not use their inhalation
medication well enough to gain optimal benefit and mini-
mize the chance of adverse effects [30].
Although the risk for oral candidiasis was highest in the
first 3 months following ICS initiation, an increased num-
ber of patients are prescribed oral candidiasis medication
after this period. The follow-up time of this study was
limited to only 1 year after ICS initiation, but if the present
trends are continued in longer follow-up periods, the
number of patients receiving oral candidiasis medication
will stay increased.
These results demonstrate not only the need for inha-
lation technique education at first prescription but also the
need for long-term follow-up instructions or periodical
inhalation checks, as suggested in earlier studies [31, 32].
Healthcare professionals in primary care, pharmacists
and general practitioners, can improve patients’ inhalation
technique by providing proper inhalation instructions.
Patient education in this respect may lead not only to
clinical improvements but also to cost reductions [33].
5 Conclusions
This study found a significant and clinically relevant
increased number of patients receiving medication for oral
candidiasis in the first year after therapy initiation with
ICS. Relative risk is highest in the first 3 months, but
remains increased up to at least 1 year after ICS initiation.
Mainly, this study stresses the need for patient education
and inhalation instruction, especially in the first 3 months
of ICS initiation but also in the long term. Pharmacists and
general practitioners can improve patient care by providing
these instructions in order to avoid this local adverse effect,
thereby increasing therapy effectiveness and patients’
quality of life and reducing waste of healthcare resources.
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